초록 ▼

Vegetable sausage analogues are provided which have texture and flavor delivery components dispersed within a set-up matrix formed from a composition including powdered vegetable protein. Included is a structured filamentous protein component which mimics connective tissue proteins of meat products.

Vegetable sausage analogues are provided which have texture and flavor delivery components dispersed within a set-up matrix formed from a composition including powdered vegetable protein. Included is a structured filamentous protein component which mimics connective tissue proteins of meat products. Other components can include thermally preformed textured proteinaceous gel phase components to mimic particles of meat protein. Further includable components are thermally structured starch carbohydrate gel crumble components which enhance flavor delivery when the sausage product is chewed.

대표청구항 ▼

Vegetable sausage analogues are provided which have texture and flavor delivery components dispersed within a set-up matrix formed from a composition including powdered vegetable protein. Included is a structured filamentous protein component which mimics connective tissue proteins of meat products.

Vegetable sausage analogues are provided which have texture and flavor delivery components dispersed within a set-up matrix formed from a composition including powdered vegetable protein. Included is a structured filamentous protein component which mimics connective tissue proteins of meat products. Other components can include thermally preformed textured proteinaceous gel phase components to mimic particles of meat protein. Further includable components are thermally structured starch carbohydrate gel crumble components which enhance flavor delivery when the sausage product is chewed. layer. 3. The capsule formulation according to claim 1, further comprising a separating layer located underneath the enteric coating layer. 4. The capsule formulation according to claim 1, wherein the dosage form comprises the proton pump inhibitor and one NSAID. 5. The capsule formulation according to claim 1, wherein the proton pump inhibitor is omeprazole, an alkaline salt of omeprazole, a single enantiomer of omeprazole or an alkaline salt of the single enantiomer. 6. The capsule formulation according to claim 5, wherein the proton pump inhibitor is S-omeprazole magnesium salt. 7. The capsule formulation according to claim 1, wherein the proton pump inhibitor is lansoprazole, a pharmaceutically acceptable salt of lansoprazole, a single enantiomer of lansoprazole or a pharmaceutically acceptable salt of the single enantiomer. 8. The capsule formulation according to claim 1, wherein the proton pump inhibitor is pantoprazole, a pharmaceutically acceptable salt of pantoprazole, a single enantiomer of pantoprazole or a pharmaceutically acceptable salt of the single enantiomer. 9. The capsule formulation according to any one of claims 5-8, wherein the NSAID(s) is selected from the group consisting of ibuprofen, diclofenac, piroxicam, naproxen and pharmaceutical acceptable salts thereof. 10. The capsule formulation according to any one of claims 5-8, wherein the NSAID is diclofenac or piroxicam, or pharmaceutically acceptable salt thereof. 11. The capsule formulation according to claim 1, wherein the amount of the proton pump inhibitor is in the range of 10-80 mg and the amount of NSAID(s) is in the range of 10-800 mg. 12. The capsule formulation according to claim 1, wherein the amount of the proton pump inhibitor is in the range of 10-40 mg and the amount of NSAID(s) is in the range of 10-500 mg. 13. The capsule formulation according to claim 2, wherein the acid resistance of the enteric coating layered pellets is in compliance with the requirements on enteric coating layered articles defined in the United States Pharmacopeia. 14. The capsule formulation according to claim 2, wherein the acid resistance of the enteric coating layered pellets does not decrease more than 10% in compliance with the requirements on enteric coating layered articles defined in the United States Pharmacopeia. 15. The capsule formulation according to claim 2, wherein the enteric coating of the individual pellets comprises a plasticizer. 16. The capsule formulation according to claim 2, wherein the enteric coating layered pellets are further covered with an over-coating layer comprising pharmaceutically acceptable excipients. 17. The capsule formulation according to claim 1, wherein the proton pump inhibitor is in the form of pellets covered with an enteric coating layer, and wherein the NSAID(s), is in the form of pellets covered with an enteric coating layer. 18. The capsule formulation according to claim 1, wherein the proton pump inhibitor is in the form of pellets covered with an enteric coating layer, and wherein the NSAID(s) is in the form of pellets coating layered with an extended release film. 19. A process for the manufacture of a capsule formulation comprising a proton pump inhibitor and one or more Non Steroidal Antiinflammatory Drugs (NSAID(s)), wherein the process comprises the steps: (a) preparing the proton pump inhibitor in the form of enteric coating layered pellets, and (b) filling a capsule with the pellets, the NSAID(s) selected from the group consisting of prepared NSAID granules, enteric coating layered NSAID pellets, and NSAID pellets coating layered with an extended release film, and optionally, pharmaceutically acceptable excipients. 20. A method for the treatment of gastrointestinal side-effects associated with NSAID treatment in mammals and man by administering to a host in need thereof a therapeutically effective dose of the capsule formulation according to any one of claims 1-8, or 11-18. 21. The method according to claim 20, wherein the disorder is an upper gastrointestinal disorder associated with NSAID treatment. 22. The capsule formulation according to any one of claims 5-8, wherein the NSAID is a NO-releasing NSAID, salt, hydrate, or ester thereof. 23. The capsule formulation according to claim 22, wherein the NO-releasing NSAID is selected from the group consisting of NO-releasing diclofenac and NO-releasing naproxen. 24. The capsule formulation according to one of claims 5-8, wherein the NSAID is a (COX)2 selective NSAID, salt, hydrate or ester thereof.